HER2-TPMC proves to be a reasonable alternative for HER2-positive cancer chemotherape
Announcing a new article publication for BIO Integration journal. Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life.